CY2076B1 - N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives - Google Patents

N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives

Info

Publication number
CY2076B1
CY2076B1 CY9802076A CY9802076A CY2076B1 CY 2076 B1 CY2076 B1 CY 2076B1 CY 9802076 A CY9802076 A CY 9802076A CY 9802076 A CY9802076 A CY 9802076A CY 2076 B1 CY2076 B1 CY 2076B1
Authority
CY
Cyprus
Prior art keywords
ylacyl
pyrrolo
pyrimidin
glutamic acid
acid derivatives
Prior art date
Application number
CY9802076A
Other languages
English (en)
Original Assignee
Univ Princeton
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2076(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/528,805 external-priority patent/US4996206A/en
Application filed by Univ Princeton, Lilly Co Eli filed Critical Univ Princeton
Publication of CY2076B1 publication Critical patent/CY2076B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY9802076A 1989-12-11 1998-09-11 N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives CY2076B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44874289A 1989-12-11 1989-12-11
US47965590A 1990-02-08 1990-02-08
US07/528,805 US4996206A (en) 1989-12-11 1990-05-24 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives
US07/528,155 US5028608A (en) 1989-12-11 1990-05-24 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives

Publications (1)

Publication Number Publication Date
CY2076B1 true CY2076B1 (en) 1998-09-11

Family

ID=27503964

Family Applications (1)

Application Number Title Priority Date Filing Date
CY9802076A CY2076B1 (en) 1989-12-11 1998-09-11 N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives

Country Status (22)

Country Link
EP (1) EP0432677B1 (ru)
JP (1) JP3016876B2 (ru)
CN (1) CN1030608C (ru)
AR (1) AR245129A1 (ru)
AT (1) ATE135007T1 (ru)
AU (1) AU640182B2 (ru)
CA (1) CA2031890C (ru)
CY (1) CY2076B1 (ru)
DE (2) DE69025723T2 (ru)
DK (1) DK0432677T3 (ru)
ES (1) ES2084639T4 (ru)
GR (1) GR3019784T3 (ru)
HK (1) HK1000920A1 (ru)
HU (1) HU218483B (ru)
IE (1) IE904445A1 (ru)
IL (1) IL96531A (ru)
LU (1) LU91147I2 (ru)
NL (1) NL300181I2 (ru)
NZ (1) NZ236385A (ru)
PT (1) PT96140B (ru)
RU (1) RU2057131C9 (ru)
SG (1) SG48098A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254687A (en) 1991-12-04 1993-10-19 The Trustees Of Princeton University Process for the preparation of pyrrolo[2,3-d]pyrimidines
US5235053A (en) * 1992-06-22 1993-08-10 Eli Lilly And Company Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
EP2266590A3 (en) 2002-02-22 2011-04-20 Shire LLC Active agent delivery sytems and methods for protecting and administering active agents
CN100344615C (zh) * 2004-11-25 2007-10-24 重庆医药工业研究院有限责任公司 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
AU2006207321B2 (en) 2005-01-21 2012-09-06 Astex Therapeutics Limited Pharmaceutical compounds
WO2008021410A2 (en) 2006-08-14 2008-02-21 Sicor Inc. Highly pure pemetrexed diacid and processes for the preparation thereof
EP2311838A1 (en) 2006-08-14 2011-04-20 Sicor, Inc. Crystalline form of pemetrexed diacid and process for the preparation thereof
EP1957497B1 (en) 2006-08-14 2015-09-30 Sicor, Inc. Processes for preparing intermediates of pemetrexed
ATE492547T1 (de) 2006-08-14 2011-01-15 Sicor Inc Verfahren zur herstellung lipophiler pharmazeutisch akzeptabler salze aus pemetrexed- disäure
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
AU2015210337B2 (en) * 2008-06-06 2017-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical combination
JP5993573B2 (ja) * 2008-06-06 2016-09-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組み合わせ
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
EP2504341A1 (en) 2009-11-24 2012-10-03 Azad Pharmaceutical Ingredients AG A new crystalline form of pemetrexed disodium
PT2854768T (pt) 2012-05-30 2017-05-19 Fresenius Kabi Oncology Ltd Composições farmacêuticas de pemetrexed
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
EP3308770A1 (en) 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
WO2014185797A1 (en) 2013-05-17 2014-11-20 Instytut Farmaceutyczny Process for the preparation of high purity amorphous pemetrexed disodium and crystalline forms of n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3- d] pyrimidin-5-yl)ethyl] benzoyl]-l-glutamic acid
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
HUE048357T2 (hu) 2014-10-16 2020-08-28 Synthon Bv Pemetrexedet tartalmazó folyékony gyógyszerészeti kompozíció
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR102511024B1 (ko) 2016-03-15 2023-03-16 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
US10793573B2 (en) * 2017-08-31 2020-10-06 Duquesne University Of The Holy Spirit First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents
CN110305135B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305137A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305134B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305136A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives

Also Published As

Publication number Publication date
ES2084639T3 (es) 1996-05-16
JPH083166A (ja) 1996-01-09
CN1030608C (zh) 1996-01-03
JP3016876B2 (ja) 2000-03-06
RU2057131C9 (ru) 2006-04-10
NZ236385A (en) 1992-05-26
EP0432677B1 (en) 1996-03-06
CA2031890A1 (en) 1991-06-12
LU91147I2 (fr) 2005-05-17
HUT58335A (en) 1992-02-28
RU2057131C1 (ru) 1996-03-27
PT96140A (pt) 1991-09-30
AU6779190A (en) 1991-06-13
DE69025723T2 (de) 1996-10-31
AR245129A1 (es) 1993-12-30
NL300181I1 (nl) 2005-05-02
NL300181I2 (nl) 2005-06-01
DE122005000012I1 (de) 2005-06-23
IL96531A0 (en) 1991-09-16
IL96531A (en) 1995-08-31
PT96140B (pt) 1997-06-30
CA2031890C (en) 2000-07-25
DK0432677T3 (da) 1996-04-09
HU218483B (hu) 2000-09-28
HU908147D0 (en) 1991-06-28
GR3019784T3 (en) 1996-07-31
EP0432677A1 (en) 1991-06-19
DE69025723D1 (de) 1996-04-11
SG48098A1 (en) 1998-04-17
IE904445A1 (en) 1991-06-19
HK1000920A1 (en) 1998-05-08
ATE135007T1 (de) 1996-03-15
DE122005000012I2 (de) 2006-02-09
CN1055182A (zh) 1991-10-09
AU640182B2 (en) 1993-08-19
ES2084639T4 (es) 2013-06-11

Similar Documents

Publication Publication Date Title
CY2076B1 (en) N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives
ZA909631B (en) N-(pyrrolo(2,3,-d)pyrimidin-3-ylacyl)-glutamic acid derivatives
ZA902185B (en) Amino acid derivatives
EP0416373A3 (en) Amino acid derivatives
EG19674A (en) Antiviral tetrahydroimidazol (1,4) denzodiazepin -2-thiones
ZA893714B (en) N-(5,6,7,8-tetrahydropyrido(2,3-d)pyrimidin-6-yl-alkanoyl)glutamic acid derivatives
ZA902444B (en) Amino acid derivatives
PH25509A (en) DIASTEREOISOMERIC TETRAHYDROPYRIDO (2,3-d)PYRIMIDINE DERIVATIVES, PROCESS THEREOF
ZA893569B (en) 1,1-dioxo-cephem-4-carbothiolic acid derivatives
GB9027494D0 (en) Imidazo(4,5c)pyridines as antiosteoporotic agents
GB8921635D0 (en) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
ZA902395B (en) Amino acid derivatives
AP9000205A0 (en) Antiviral tetrahydroimidazo(1,4)benzodia-zepines
GB8909277D0 (en) 3-alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
ZA903999B (en) Mevinic acid derivatives
ZA907585B (en) Amino acid derivatives
IE871498L (en) PYRRIDAZINO (4,5:3,4) PYRROLO (2,1-a) ISOQUINOLINES
ZA901366B (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-thiones
GB8920354D0 (en) Antiviral tetrahydroimidazo(1,4)benzodiazepin-2-thiones
IE893838L (en) ß-AMINOBORONIC ACID DERIVATIVES
ZA902133B (en) Acrylamido-penicillanic acid derivatives
ZA908085B (en) Imidazole-hept-6-enoic acid derivatives
GB8918937D0 (en) Acid derivatives
IE851649L (en) PYRROLO (1,2-b) TRIAZEPINE
IE892083L (en) Amino acid derivatives.